Redburn Atlantic initiated coverage of Alnylam with a Buy rating and $353 price target Therapeutic options for patients with transthyretin ...
Abbott (NYSE: ABT) today announced data demonstrating substantial, sustained improvements with its TriClip system.
Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved ...
News-Medical.Net on MSN3h
Fluid restriction does not improve health in heart failure patientsPeople with heart failure have long been advised to limit the amount of fluids they consume each day to help reduce congestion, or the buildup of fluid in the lungs and extremities, but that advice ...
FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR ...
A program that delivered in-home visits from a trained paramedic team to people with heart failure did not significantly reduce 30-day hospital ...
Your Horse on MSN1h
Inspiring rider with terminal cancer, a pony with dwarfism and a bridleless mare: celebrating the best of #Hack1000MilesAs a new #Hack1000Miles year gets underway, let’s take a moment to celebrate some of the stand-out stories of 2024. From the ...
Researchers at ACC suggested stratifying by age and TTR variant, plus cascade testing, could help identify those likely to ...
Abbott today announced late-breaking data from its TRILUMINATEtm Pivotal trial that show the TriCliptm transcatheter edge-to-edge repair (TEER) system to treat tricuspid regurgitation (TR), or a leaky ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback